Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
19 Years
70 Years
Both
Breast Cancer
Trial Information
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous
Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin
for Stage IV Breast Cancer & Limited Prior Treatment
Inclusion Criteria:
- stage IV breast cancer- primary breast cancer does not express CD34+
- adequate organ function
- no evidence of active infection
Exclusion Criteria:- chemotherapy within 4 weeks
- CNS disease
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Feasibility and safety
Outcome Time Frame:
unknown
Safety Issue:
Yes
Principal Investigator
Ginna Laport
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
BMT86
NCT ID:
NCT00186680
Start Date:
September 1996
Completion Date:
June 2005
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
